World Adjunctive Cancer Therapies Market Expected to Top $24 Billion by 2010

New York, April 21, 2006— With more than 10 million new cases of cancer diagnosed throughout the world every year, revenues from adjunctive therapies used to relieve the side effects of both primary cancer treatments and the disease itself are growing at an annual rate of 7.4% and are expected to reach $24.5 billion by 2010.

According to The Global Market for Adjunctive Therapies in Cancer, a new study released today from Kalorama Information, 2005 revenues for therapies addressing nausea, anemia, pain, and infections, among others, exceeded $17 billion. Indeed, from 2003 to 2005, the market grew by nearly 15%, primarily due to strong sales of biological response modifiers, and nausea, emesis, and breakthrough pain management therapies.

Yet worldwide, the focus remains on cancer cures. A variety of factors, such as cost and poor healthcare infrastructure, lack of awareness of available therapies, and financial provisions encouraging aggressive cancer treatment rather than symptomatic relief, have limited the scope of therapy options. Hence the development of therapy and delivery options to minimize side effects, such as pain, fatigue, immunosuppression, and memory loss, are not being adequately addressed.

“This inability to look beyond the ‘race for the cure,’ has left millions of cancer suffers without adequate relief of their often debilitating side effects,” notes Melissa Elder, the report’s author. “Providers need to understand that aggressive management of ancillary symptoms can be vital to the ultimate success of primary treatment. More proactive messaging from manufacturers on this topic could lead to even greater revenues than we’ve projected.”

The study examines the global market for antinauseants and antiemetics, pain management, blood modifiers, infection control, and other therapies used to treat and manage symptoms in cancer patients.

The Global Market for Adjunctive Therapies in Cancer also includes research and development pipelines, in-depth company profiles, four-region geographic breakdowns, the epidemiology of side effects, and more. It can be purchased directly from Kalorama Information by clicking http://www.kaloramainformation.com/pub/1190815.html. It is also available at MarketResearch.com.

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, a leading provider of industry-specific market research reports, supplies the latest in independent market research for the life sciences. For more information, contact Tom Ehart at 240-747-3014 or tehart@marketresearch.com, or visit www.KaloramaInformation.com.